Crocker Ventures
Crocker Ventures is a privately held, family-office style investment firm founded by Gary L. Crocker that deploys internally funded patient capital into seed- and early-stage companies across biotechnology, medical devices, drug delivery, diagnostics, and information technology.
- Company typePrivate
- Founded2004
- HeadquartersSalt Lake City, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Crocker Ventures does
Crocker Ventures is an independent, privately held investment firm founded in 2004 by Gary L. Crocker and headquartered in Salt Lake City, Utah. The firm invests Crocker-family capital into promising seed- and early-stage companies across five vertical areas: biotechnology and pharmaceuticals, medical devices, drug delivery, diagnostics, and information technology. Unlike traditional venture capital funds, Crocker Ventures is internally funded rather than backed by external limited partners, which removes fund-return timeline pressure and enables long-duration, patient capital deployment — a structural fit for life science companies that require extended development cycles.
The firm does not sell products or services to end customers and does not operate a technology platform; its "product" is capital, operating expertise, and strategic relationships supplied to portfolio companies. Current disclosed portfolio comprises approximately 15 companies spanning operating businesses (Nexus Spine, TMClear, Nexus CMF, Rebel Medicine, AGADA Medical, Xenocor) and earlier-stage investment holdings (Coupang, Sirona Medical, Angel Studios, Obra, IsoTalent, AZIsotopes, Silver Creek Pharmaceuticals, TellBio, Akagera Medicines). Portfolio companies operate across Utah, California, Massachusetts, Indiana, and Israel.
The firm's economic model is realized through episodic exits rather than recurring revenue. Crocker Ventures' track record includes Research Medical's $235 million sale to Baxter in 1997, Theratech's $340 million sale to Watson Pharmaceuticals in 1999, and Merrimack Pharmaceuticals' public listing with FDA-approved ONIVYDE, aggregating to over $800 million in disclosed realized exit value. Gary Crocker also serves as Chairman of Merrimack (since 2004) and previously chaired ARUP Laboratories (1998–2003), reinforcing an operating-heavy engagement model centered on life sciences.
Crocker Ventures firmographics
Firmographics- Name
- Crocker Ventures
- Legal name
- Crocker Ventures
- Website
- https://crockerventures.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Crocker Ventures is a privately held, family-office style investment firm founded by Gary L. Crocker that deploys internally funded patient capital into seed- and early-stage companies across biotechnology, medical devices, drug delivery, diagnostics, and information technology.
- Ownership category
- akta.pro rank
Crocker Ventures industry classification
Industry- Product category
- Venture Capital and Private Equity
- NAICS
- Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Independent Venture Debt Funds / Platforms (FSANAIAB)
Keywords
Where Crocker Ventures is headquartered
LocationHeadquarters
- HQ city
- Salt Lake City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Crocker Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
Distribution channels1 record
Marketing channels2 records
Crocker Ventures product offering
Product offeringCore offering
Crocker Ventures is an independent, privately held investment firm that provides seed- and early-stage capital to companies operating in five primary areas: biotechnology/pharmaceuticals, medical devices, drug delivery, diagnostics, and information technology. The firm supplies patient capital without limited partner timeline constraints, alongside operational expertise, strategic relationships, and mentorship to portfolio companies targeting large unmet market needs.
Product overview
Crocker Ventures is an independent, privately held life science, healthcare and technology investment firm that does not offer its own products or services. The firm funds promising seed- and early-stage companies in five primary areas: biotechnology/pharmaceuticals, medical devices, drug delivery, diagnostics, and information technology. Their portfolio includes operating companies (Nexus Spine, TMClear, Nexus CMF) and investment companies (AGADA Medical, Coupang, Xenocor, Rebel Medicine, IsoTalent, Obra, AZIsotopes, Sirona Medical, Angel Studios, Silver Creek Pharmaceuticals, TellBio, Akagera Medicines).
Differentiator
Problem solved
Functional benefit
Products and services
- Seed- and Early-Stage Venture Capital Funding Equity capital investment in seed- and early-stage companies across biotechnology/pharmaceuticals, medical devices, drug delivery, diagnostics, and information technology. The firm supplies patient capital without limited partner timeline constraints along with operational expertise, strategic relationships, and mentorship to portfolio companies.
Companies that use Crocker Ventures
Customer profileSegments1 record
Ideal customer profiles1 record
Crocker Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Crocker Ventures partnerships and signals
Strategic signalScale indicators6 records
Recent moves4 records
Expansion highlights4 records
Crocker Ventures competitors and assessment
Company assessmentDirect peers
- ARCH Venture Partners: ARCH Venture Partners is a long-tenured venture firm investing in early-stage life science, physical science, and information technology companies. Comparable in broad life science + tech thesis and willingness to underwrite long development cycles.
- Atlas Venture: Atlas Venture is a life sciences-focused early-stage venture capital firm that builds and funds biotech startups across modalities and therapeutic areas. It directly matches Crocker Ventures' seed/early-stage life science investing mandate with operating-style involvement.
- Third Rock Ventures: Third Rock Ventures is a healthcare venture firm that builds biotech companies from inception with active operational leadership from partners. Parallels Crocker Ventures' hands-on founding/investing approach in life sciences.
- Versant Ventures: Versant Ventures is a healthcare-focused venture capital firm that invests across biotech, medtech, and digital health from seed through growth. Comparable in stage range and life science/tech breadth to Crocker Ventures.
- 5AM Ventures: 5AM Ventures is a life sciences venture capital firm investing in early-stage biotech companies with active scientific involvement. Matches Crocker Ventures' seed/early-stage life science focus and operating engagement.
- Flagship Pioneering: Flagship Pioneering is a life sciences creation and venture firm that originates and funds platform biotech companies with deep operating involvement. Comparable to Crocker Ventures in its operator-investor model and concentration on life science seed and early-stage innovation.
Broad incumbents
- OrbiMed Advisors: OrbiMed is a large, established healthcare investment platform spanning venture, growth, and public equities across therapeutics, medical devices, and diagnostics. Comparable to Crocker Ventures in life science focus but at materially greater AUM scale.
- Deerfield Management Company: Deerfield Management is an investment firm dedicated to healthcare, with strategies spanning venture, public equities, and credit. Comparable life science concentration but much broader in scale and instrument type than Crocker Ventures.
- New Enterprise Associates (NEA): NEA is a large diversified venture capital firm with a significant healthcare and life sciences practice alongside technology. Comparable life science exposure at scale, with a venture-stage focus overlapping Crocker Ventures' thesis areas including medical devices, drug delivery, and diagnostics.
- SR One (GlaxoSmithKline): SR One is the corporate venture arm of GSK, focused on early-stage life science and biotech investments. Comparable life science seed/early-stage mandate and pharma relationship-driven strategy to Crocker Ventures.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Crocker Ventures social profiles
Digital presenceCrocker Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Crocker Ventures leadership team
Management profileNumber of profiles
Profiles1 record
Crocker Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Crocker Ventures M&A and investment
M&A and investmentM&A1 record
Investments6 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Crocker Ventures
What does Crocker Ventures do?
Crocker Ventures is an independent, privately held investment firm that provides seed- and early-stage capital to companies operating in five primary areas: biotechnology/pharmaceuticals, medical devices, drug delivery, diagnostics, and information technology. The firm supplies patient capital without limited partner timeline constraints, alongside operational expertise, strategic relationships, and mentorship to portfolio companies targeting large unmet market needs.
Is Crocker Ventures a public or private company?
Crocker Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Crocker Ventures founded?
Crocker Ventures was founded in 2004. It employs 11 to 50 people.
Where is Crocker Ventures based?
Crocker Ventures is headquartered in Salt Lake City, United States, in the North America region.
Who are Crocker Ventures's main competitors?
Direct peers on record are ARCH Venture Partners, Atlas Venture, Third Rock Ventures, Versant Ventures, 5AM Ventures and Flagship Pioneering. Broad incumbents are OrbiMed Advisors, Deerfield Management Company, New Enterprise Associates (NEA) and SR One (GlaxoSmithKline).
Does Crocker Ventures have an API?
No public API is recorded for Crocker Ventures.
What industry is Crocker Ventures in?
Crocker Ventures's product category is Venture Capital and Private Equity. Its primary akta.pro industry code is FSANAIAB, Independent Venture Debt Funds / Platforms. Its NAICS code is 523940 and its SIC code is 6282.